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Abstract: Alternative splicing of pre-mRNA helps to enhance the genetic diversity within mammalian
cells by increasing the number of protein isoforms that can be generated from one gene product. This
provides a great deal of flexibility to the host cell to alter protein function, but when dysregulation in
splicing occurs this can have important impact on health and disease. Alternative splicing is widely
used in the mammalian immune system to control the development and function of antigen specific
lymphocytes. In this review we will examine the splicing of pre-mRNAs yielding key proteins in
the immune system that regulate apoptosis, lymphocyte differentiation, activation and homeostasis,
and discuss how defects in splicing can contribute to diseases. We will describe how disruption to
trans-acting factors, such as heterogeneous nuclear ribonucleoproteins (hnRNPs), can impact on cell
survival and differentiation in the immune system.
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1. Introduction
The immune system has evolved to respond to a myriad of pathogens. It is composed of two
effector arms known as the innate and adaptive immune systems and they have specialized roles to
play in protecting the host from infectious diseases and maintaining long-term health [1,2]. The innate
immune system is composed of physical barriers such as the skin and mucous membranes but it is
also composed of specialized cells such as macrophages, dendritic cells and granulocytes including
neutrophils, basophils and mast cells. Many of these cells have a phagocytic function to help remove
cellular debris and pathogens to maintain tissue homeostasis. These innate immune cells play a critical
role to trigger adaptive immune responses [1,2]. Importantly these innate immune cells lack expression
of antigen specific receptors but instead rely on expression of a range of evolutionarily conserved
pattern recognition receptors to identify microbial derived components including proteins, lipids,
carbohydrates and nucleic acids [3].
The adaptive immune system is composed of T and B lymphocytes and they are able to generate
specific immune responses to defined antigens, and can generate immunological memory. B cell
lineage differentiation occurs in the bone marrow and mature B cells are the major antibody producing
cells of the immune system. B cells express an antigen-specific and clonally restricted receptor known
as an immunoglobulin (Ig) molecule or B cell receptor (BCR). T cell lineage differentiation is restricted
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to the thymus and as they mature T cells express a clonally restricted T cell receptor (TCR) and develop
into two major lineages referred to as TCRαβ+ and TCRγδ+. The TCRαβ+ lineage represents the major
population of T cells in the peripheral immune system comprising >90% of the total T cells. These cells
can give rise to two distinct subsets referred to as CD4+ Thelper (Th) cells which help B cells to produce
antibodies and CD8+ cytotoxic T cells (CTLs) which help to recognize and destroy virus infected cells
and tumor cells. In contrast, the TCRγδ+ cells play a role in immune surveillance in a range of tissues.
In addition to TCRαβ+ and TCRγδ+ T cells, Natural Killer T (NKT) cells and NK cells also arise during
thymic development.
Alternative splicing of pre-mRNA is prevalent in mammalian genomes and acts as a mechanism
to amplify genetic diversity by enabling the number of proteins arising from the genes to be increased
by a factor of 10 times [4]. Alternative pre-mRNA splicing can also regulate protein expression in
a cell-specific or tissue-specific manner in response to precise environmental or developmental cues.
Multiple variants of protein (isoforms) can be produced from a single gene [5,6]. Alternative splicing
offers flexibility to the transcriptome and proteome to help fine tune important and complex cellular
responses such as regulation of cell viability, differentiation and apoptosis in response to environmental
cues [7]. Mutations that disrupt the process of alternative splicing from pre-mRNAs to proteins can be
deleterious to health and readers are referred to a more comprehensive review on the topic by Cooper,
Wan and Dreyfuss [8].
The immune system must be able to distinguish between self and non-self to protect against the
risk of autoimmunity, and this helps to mount an appropriate immune response to neutralize and
remove infectious (non-self) agents that cause disease. The immune system has to balance the need to
remove autoreactive T and B cells during their development that express self-reactive receptors and to
maintain a sufficiently diverse lymphocyte repertoire to be able to respond to any infectious agent.
One of the best examples of alternative splicing in the immune system is the generation of the diverse
repertoire of antigen receptors expressed by B and T cells that can recognize a wide range of protein
antigens [9,10]. Apoptosis is a critical mechanism for regulation of immune tolerance to self-antigens.
The immune system also uses apoptosis to regulate the turnover of lymphocytes throughout life which
is referred to as lymphocyte homeostasis, and is vital in the resolution of immune responses to kill off
effector cells once a pathogen has been cleared [11]. It has emerged in recent years that a number of the
proteins involved in regulation of apoptosis from cell surface receptors to signaling proteins involved
in the effector pathway of cell death are controlled at the level of alternative splicing of pre-mRNA.
Therefore, in this review we will examine the key role for apoptosis regulators and highlight where
defects in alternative splicing can have important consequences on the decision between immunity
and tolerance and on lymphocyte homeostasis. We will also examine the role of specific heterogeneous
nuclear ribonucleoproteins (hnRNPs) in the regulation of pre-mRNA alternative splicing to illustrate
how these proteins can impact on immune cell development and function.
2. Alternative Splicing of Pre-mRNA
Alternative pre-mRNA splicing considerably expands the genome’s “vocabulary” of variant
genes, resulting in different functions and outcomes within the cell [6]. As a result metazoans depend
on alternative splicing as their major contributor to protein diversity [5,7]. Alternative splicing results
in the rearrangement of exons within a multi-exon pre-mRNA. Specific internal “cassette” exons can be
spliced out or included in the final mRNA [5] (Figure 1). The mRNA transcript can also be rearranged
by altering exon splice sites (SS) resulting in a lengthened or shortened exon [5]. Both the 51 and 31
SS can be altered. There can be alternative usage of 51 or 31 untranslated regions (UTRs) that can
influence whether or not regulatory sequences are present for a splicing factor to bind or they may
contain sequences which promote binding of microRNAs [12,13]. Collectively these modifications
can influence the stability expression and translation of specific mRNA transcripts. 51 UTRs are
altered with the use of alternative promoters and splicing and 31-terminal exons are altered by splicing
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an alternative polyadenylation site [5]. The failure to remove introns, known as intron retention, is
another mechanism that results in alternative splicing [5].Int. J. Mol. Sci. 2016, 17, 0003 3 of 21 
 
 
Figure 1. Mechanism of alternative splicing of pre-mRNAs. The cis-regulatory elements that control 
alternative splicing are composed of unique nucleotide sequences. The exonic splicing enhancers 
(ESE) and intronic splicing enhancers (ISE) (dark blue) respectively promote exon inclusion (light blue 
boxes), while exon repression requires the exonic splicing silencer (ESS) and intronic splicing silencer 
(ISS) elements (brown). The trans-acting factors that promote exon inclusion are the Serine (S)-
Arginine (R) SR rich proteins while hnRNP proteins can promote exon skipping. In the diagram the 
middle exon can be included to give rise to a polypeptide with 3 exon units, while the alternatively 
spiced polypeptide skips the variable exon to yield a protein with 2 exon units. 
The process of intron removal and exon joining is catalyzed by the enzymatic complex referred 
to as the spliceosome. This is a multiprotein complex that is assembled de novo on pre-mRNA 
transcripts. Nuclear pre-mRNA splicing involves two simple ATP-dependent chemical reactions 
known as SN2-type trans-esterification reactions, which involve three reactive regions in the pre-
mRNA [14]. First the branch point sequence (BPS) in the intron breaks the phosphodiester bond at 
the 5′ SS. This generates a free 5′ exon and a structure known as an intron lariat-3′ exon. A second 
phosphodiester bond is broken at the 3′ SS by the 3′ hydroxyl of the 5′ exon resulting in exon ligation 
and excision of the lariat intron. The folding of nuclear pre-mRNA introns to enable splicing is 
dependent on trans-acting factors that comprise the spliceosome. This dependency does not occur in 
self-splicing group II introns that are able to adopt a three-dimensional fold for splicing by themselves 
[15]. The human spliceosome consists of a single non coding RNA (snRNA) that contains uridine-
rich small nuclear ribonucleoproteins (snRNPs) named U1, U2, U4/U6 and U5 and ~45 distinct 
snRNP-associated proteins [16]. In addition to snRNP associated proteins, studies have shown that 
there are approximately 170 spliceosome-associated factors with individual assembly intermediates 
each containing around 125 proteins (see review by Wahl, Will and Luhrmann for the different 
spliceosome assemblies and conformations that occur during splicing [16]). 
Many factors determine whether or not a pre-mRNA sequence will be alternatively spliced. For 
example, the inclusion or exclusion of an exon is determined by the ability of the spliceosome to 
recognize the exon’s surrounding SS that are determined by cis elements that help in regulating SS 
selection by modulating the interaction with snRNP and its substrate. The recognition of the 
spliceosome to the exon’s SS results in the formation of the exon-definition complex [16]. Different 
factors can inhibit or enhance spliceosomal recognition of these SS, with splicing regulatory 
sequences more commonly found in introns rather than exons [5,17]. Binding sites for regulators are 
often found immediately adjacent to the BPS or 5′ SS or within the polypyrimidine tract [5]. Some 
regulatory sequences are capable of regulating exons hundreds of nucleotides away from their 
location, such as the dsx repeat element (dsxRE), a splicing enhancer found in Drosophila melanogaster 
[18]. Cis-regulatory sequences referred to as intronic and exonic splicing enhancers (ISE and ESE) can 
promote or intronic and exonic splicing silencers (ISS and ESS) can suppress the assembly of the 
snRNP on the substrate (Figure 1). There are two protein families of trans-acting regulatory proteins 
the Serine (S)-Arginine (R) rich (SR) and the hnRNPs that act to recruit the spliceosome machinery to 
the SS [19–21] (Figure 1). The SR proteins tend to enhance SS usage whereas hnRNP proteins favor 
exon skipping (Figure 1), but this is not a strict rule as there are examples which are contrary to this 
generalization [22–24]. Both families of RNA binding proteins can exhibit enhancing and silencing 
Figure 1. echanis of alternative splicing of pre- RNAs. The cis-regulatory ele ents that control
alternative splicing are composed of unique nucleotide sequences. The exonic splicing enhancers (ESE)
and intronic splicing enhancers (ISE) (dark blue) respectively promote exon inclusion (light blue boxes),
while exon repression requires the exonic splicing silencer (ESS) and intronic splicing silencer (ISS)
elements (brown). The trans-acting factors that promote exon inclusion are the Serine (S)-Arginine
(R) SR rich proteins while hnRNP proteins can promote exon skippi g. In the diagram the middle
exon can be included to give rise to a polypeptide with 3 exon units, while the alternatively spiced
polype tide skips the variable exon to yield a protein with 2 exon units.
The process of intron removal and exon joining is catalyzed by the enzymatic complex referred to
as the spliceosome. This is a multiprotein complex that is assembled de novo on pre-mRNA transcripts.
Nuclear pre-mRNA splicing involves two simple ATP-dependent chemical reactions known as
SN2-type trans-esterification reactions, which involve three reactive regions in the pre-mRNA [14].
First the branch point sequence (BPS) in the intron breaks the phosphodiester bond at the 51
SS. This generates a free 51 exon and a structure known as an intron lariat-31 exon. A second
phosphodiester bond is broken at the 31 SS by the 31 hydroxyl of the 51 exon resulting in exon
ligation and excision of the lariat intron. The folding of nuclear pre-mRNA introns to enable splicing
is dependent on trans-acting factors that comprise the spliceosome. This dependency does not
occur in self-splicing group II introns that are able to adopt a three-dimensional fold for splicing
by themselves [15]. The human spliceosome consists of a single non coding RNA (snRNA) that
contains uridine-rich small nuclear ribonucleoproteins (snRNPs) named U1, U2, U4/U6 and U5 and
~45 distinct snRNP-associated proteins [16]. In addition to snRNP associated proteins, studies have
shown that there are approximately 170 spliceosome-associated factors with individual assembly
intermediates each containing around 125 proteins (see review by Wahl, Will and Luhrmann for the
different spliceosome assemblies and conformations that occur during splicing [16]).
Many factors determine whether or not a pre-mRNA sequence will be alternatively spliced.
For example, the inclusion or exclusion of an exon is determined by the ability of the spliceosome
to recognize the exon’s surrounding SS that are determined by cis elements that help in regulating
SS selection by modulating the interaction with snRNP and its substrate. The recognition of the
spliceosome to the exon’s SS results in the formation of the exon-definition complex [16]. Different
factors can inhibit or enhance spliceosomal recognition of these SS, with splicing regulatory sequences
more commonly found in introns rather than exons [5,17]. Binding sites for regulators are often found
immediately adjacent to the BPS or 51 SS or within the polypyrimidine tract [5]. Some regulatory
sequences are capable of regulating exons hundreds of nucleotides away from their location, such as
the dsx repeat element (dsxRE), a splicing enhancer found in Drosophila melanogaster [18]. Cis-regulatory
sequences referred to as intronic and exonic splicing enhancers (ISE and ESE) can promote or intronic
and exonic splicing silencers (ISS and ESS) can suppress the assembly of the snRNP on the substrate
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(Figure 1). There are two protein families of trans-acting regulatory proteins the Serine (S)-Arginine (R)
rich (SR) and the hnRNPs that act to recruit the spliceosome machinery to the SS [19–21] (Figure 1).
The SR proteins tend to enhance SS usage whereas hnRNP proteins favor exon skipping (Figure 1),
but this is not a strict rule as there are examples which are contrary to this generalization [22–24].
Both families of RNA binding proteins can exhibit enhancing and silencing activity when bound to
an intron [25]. The ISE and ESE elements are found in both constitutive and cassette exons and appear
to be a means of defining exons [21,26].
The relative affinity of the 51 SS and 31 SS determines the particular snRNP that will bind to the
specific SS. This plays an important role as the consensus sequences that make up the 51 SS, 31 SS
and BPS are degenerate in higher eukaryotes where alternative splicing is predominant [5]. This also
results in SS alone not being capable of efficiently directing spliceosomal assembly. SR and hnRNP
proteins are therefore required to manage and direct the spliceosome [5]. SR proteins bind with
low affinity and specificity to both the pre-mRNA and other Arginine (R)-Serine (S) (RS) domain
containing spliceosomal proteins. Interestingly, SR proteins for the most part are absent in yeast with
exceptions such as the SR-like protein Npl3 [27]. The addition of SR proteins in metazoans correlates
with the degeneration of the consensus sequences defining the 51 SS, 31 SS and BPS [5]. They also share
a common domain structure consisting of one or two RNA recognition motifs (RRMs) followed by
a RS domain containing RS dipeptides [19]. These serine dipeptides can be highly phosphorylated [28].
High throughput sequencing of chromatin associated RNA in Drosophila revealed that splicing of
genes can occur in a co-transcriptional manner and the efficiency of the co-transcriptional splicing
varies between genes [29]. The variability in efficiency of co-transcriptional splicing is thought to be
regulated at the level of the intron and is mediated by different RNA binding proteins such as SR and
hnRNP proteins [29]. Furthermore, there is a direct correlation between those genes where there is no
co-transcriptionally splicing with annotated alternative exons. [29–31].
Alterations to the activity of splicing factors can be influenced by posttranslational
modification [28,32]. In a large scale phosphoproteomic analysis of TCR signaling in the Jurkat T cell
line Mayya et al. [33], identified that splicing factors and components of the spliceosome can be targets
of TCR induced phosphorylation. This is important as both hypo- and hyper-phosphorylation of SR
proteins in vitro has been demonstrated to modulate protein function [28,34]. These posttranslational
modifications can influence protein-protein interactions as well as protein–RNA interactions to regulate
their activity and to direct expression of different isoforms of proteins with different functions that
derive from a common pre-mRNA. The hnRNP proteins hnRNPLL and CELF2 function in alternative
splicing and expression of both proteins is linked to TCR signaling [35,36]. In the following discussion
we want to explore the role of a range of well characterized RNA binding proteins that are involved in
alternative splicing in the immune system.
3. HnRNP Proteins and Their Role in Pre-mRNA Alternative Splicing
Alternative splicing plays an important role to alter the biological function of key immune proteins
and this can impact on the host’s immune response [37]. One of the first genes identified in B and T
cells to undergo alternative splicing was the Ptprc encoding the CD45 protein which is an abundant
tyrosine phosphatase found on the surface of most leukocytes [38–41]. CD45 regulates TCR signaling
by dephosphorylating two regulatory tyrosine residues (Lck Y505 and Lck Y394) on the Src kinase
p56lck [20,42,43]. In addition to its tyrosine phosphatase function it has also been shown to have
an important role in cell survival and death [38,44,45]. CD45 is expressed specifically on all nucleated
hematopoietic cells and their precursors and comprises up to 10% of cell surface protein in T and
B cells [46]. The Ptprc gene has three variable cassette exons (exons 4, 5 and 6), which encode the
CD45RA, RB and RC segments that undergo extensive posttranslational modification by the addition
of numerous O-glycosylation sites within the extracellular domain [47]. These different CD45 isoforms
are used to distinguish recently activated and antigen-experienced cells from naïve T cells [40,45].
In B lymphocytes Ptprc is spliced to include all three exons and is termed B220 or CD45RABC [48].
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Naïve T cells express CD45 isoforms which include one (CD45RB) to two (CD45RAB/CD45RBC) of
the cassette exons [40,45]. In contrast, memory T cells express the CD45RO isoform which lacks all
three exons [40,45].
These different isoforms of CD45 are highly conserved and tightly regulated throughout
development and are linked to activation status of the T cell [38,40,49,50]. There are functional
differences between the different isoforms with the lower molecular weight isoforms, such as CD45RO,
being more prone to homodimerization and subsequent auto-inhibition resulting in T cell signaling
attenuation than the higher molecular weight isoforms [50,51]. Absence of CD45 isoforms on the cell
surface results in impairment of both T and B cell activation and subsequent proliferation and cytokine
production [46,48,52]. As a result their expression is tightly regulated during development and is
linked with cellular activation in response to antigen receptor signaling [53]. A range of different
hnRNP proteins, which will be discussed further below, have been shown to play a role in alternative
splicing of CD45 pre-mRNA and are dependent on TCR dependent activation of Protein Kinase C PKC
and Ras [54]. The hnRNP proteins act as ESS-responsive negative regulators of splicing and are thus
antagonistic to SR proteins [55–57]. Changes in the level of endogenous hnRNP proteins can mediate
important pre-mRNA splicing modifications that result in different cell functions [55].
3.1. HnRNPL
HnRNPL is an RNA binding protein that has four RRM domains and can act as both a splicing
enhancer as well as splicing silencer. In addition to its role in regulating inclusion of cassette exons it
can also function in intron retention and polyadenylation site choice [24,58–60]. The hnRNPL protein
was one of the first trans-acting factors identified in regulating the splicing of the three variable exons
(4, 5 and 6) of the Ptprc gene. Splicing of the three variable exons of CD45 was shown to be linked to
TCR signaling in naïve T cells and is dependent on the presence of an activation response sequence
(ARS) within each of the exons of the variable exons [50,60] (Figure 2). The ARS motif is located
within a 60 nucleotide sequence of the ESS1 of exons 4 and 6. Identification of the ARS motif helped to
identify proteins that are involved in regulation of splicing of these three variable exons. HnRNPL
was identified as the basal mediator of repression of Ptprc variable exons [24,50,60,61] (Figure 2).
Thymocytes from Hnrnpl´{´ mice show increased inclusion of the CD45 exons that helped to confirm
the important role for the hnRNPL protein in vivo for CD45 exon repression [62]. The Hnrnpl´{´ mice
were healthy but revealed an arrest in thymocyte differentiation at the double negative to double
positive transition that in turn leads to a marked decrease in thymic cellularity.
3.2. HnRNPLL
The hnRNPLL protein has four RRM domains and is upregulated following TCR signaling in
resting T cells and is also highly expressed in memory T cells [31]. The functional role for hnRNPLL in
T cells has been uncovered through the use of cell based assay systems as well as studies with a novel
mouse strain that expresses a loss-of-function allele of Hnrnpll generated by N-ethyl-N nitrosourea
(ENU) mutagenesis in mice [26]. Topp et al. [61] identified hnRNPLL as a protein that bound to the ARS
motif of exon 4 to mediate its repression while in an alternative approach Oberdoerffer et al. [63] used
an shRNA genetic screen to identify hnRNPLL as an important factor that regulates repression of exon
4 of CD45 (Figure 2). The studies by Wu et al. [26] identified a novel ENU induced allele in a mouse
strain caused by a point mutation V136D within the RRM1 domain and this led to destabilization of
the domain leading to a loss of protein function. In contrast to hnRNPL, the hnRNPLL protein does
not bind to the ARS motif in exon 5 of Ptprc and does not have any effect on the activation induced
repression of exon 5 [24,63]. Hnrnpll expression is strongly induced following TCR activation and this
leads to recruitment of the hnRNPLL protein to the ARS sequence of exon 4 and exon 6 where it can
associate with hnRNPL leading to repression of the variable exons (Figure 2). Cho et al. [64], identified
that hnRNPLL can induce a distinct pattern of intron retention surrounding target cassette exons in
T cells. In particular three genes Senp2, Ctse and Slc12a7 displayed greater intron retention in wild type
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cells compared to cells containing the hnRNPLLthunder allele and in the wild type cells this correlated
with exon inclusion. Furthermore, they validated the splicing of 15 genes by PCR and revealed 8 out
of the 15 selected genes that displayed differential bands between wild type and hnRNPLLthunder T
cells (Degs1, Sidt1, Mapkap3, Herc3, Ikbe, Cep110, Mllt6 and Rap1gds1) [64]. They believe that hnRNPLL
can act as a splicing silencer and a splicing enhancer and this varies between different genes.Int. J. Mol. Sci. 2016, 17, 0003 6 of 21 
 
 
Figure 2. Alternative splicing of the Ptprc gene. The Ptprc gene can give rise to multiple isoforms 
through alternative splicing of pre-mRNA that involves three variable exons 4, 5 and 6. All three 
variable exons contain the ARS motif (black) and the ESE (black). The upper panel indicates the 
conditions of alternative splicing in T cells in the basal resting state. The hnRNPL protein mediates 
basal repression of exon 4 in resting cells, while the SR protein SRSF1 mediates the inclusion of exon 
5. In addition, the CTCF protein can bind to the ESE sequence of exon 5 to mediate pausing of the 
RNAPII elongation to promote exon 5 inclusion. The bottom panel shows the alternative splicing of 
Ptprc gene following TCR activation. The proteins PSF and hnRNPLL are recruited to the exon 4 and 
exon 6 ARS together with hnRNPL to promote repression of both exons, while hnRNPL and PSF 
mediate repression of exon 5. 
3.3. Polypyrimidine-Tract-Binding Protein (PTB)-Associated Splicing Factor (PSF) 
The PSF protein is an hnRNP protein that contains two RRM domains and was originally 
identified as an essential trans-acting factor to regulate splicing of the variable exons of Ptprc [65,66]. 
PSF, like hnRNPLL, displays preferential binding to the ESS1 element of exon 4 of the Ptprc gene, but 
its association with the ESS1 motif is independent of both hnRNPL and hnRNPLL. PSF does not bind 
to the canonical ARS motif but to sequences outside of the core motif [61,66] (Figure 2). Recruitment 
of PSF to the CD45 ARS motif requires posttranslational modification of the protein via the 
serine/threonine kinase glycogen synthase kinase 3 (GSK3). In resting cells GSK3 phosphorylates PSF 
which facilitates its interaction with TRAP150, and the PSF-TRAP150 complex prevents PSF form 
binding to the ARS motif. Following T cell activation, the activity of GSK3 is inhibited which prevents 
phosphorylation of PSF and this allows recruitment of PSF to the ARS motif to mediate repression of 
the variable exons. Martinez and Lynch have proposed that the PSF-TRAP150 complex is likely to 
control a broader set of alternatively spliced pre-mRNAs in T cells [25]. 
3.4. Serine/Arginine-Rich Splicing Factor 1 (SRSF1) 
The SRSF1 protein is a member of the SR protein family and it contains an N-terminal RRM-
domain and a C-terminal RS rich domain which is thought to be involved in protein-protein 
interactions. The SRSF1 protein has been implicated in splicing of a number of immune pre-mRNAs 
including CD45 exon 5 and for the retention of an intron within the 3′ UTR region of the CD3ζ protein 
which is involved in the formation of the CD3 complex that is required for TCR signaling. SRSF1 can 
bind to the ESE sequence in exon 5 of the Ptprc gene. Exon 5 contains two ARS motifs which are 
separated by the ESE. SRSF1 can bind to the ESE and promote inclusion of exon 5 whereas hnRNPL 
can bind to the ARS sequence and mediate exon repression (Figure 2). It is believed that there is a 
i . lt ti li i f t t . t i i t lti l i f
, 6.
ti ( l t e ES (black).
r sti st t .
, i
i t ro ote exon 5 inclusion. The bottom panel shows the alternative splicing
of Ptprc g ne f llowing TCR activation. The proteins PSF and hnRNPLL are recrui ed to the exon 4
and exon 6 ARS tog ther with hnRNPL to promote repression of both exons, while hn PL
.
. . l i i i - t- i i rotei ( )- ssociated Splicing Factor (PSF)
PSF protein is an h RNP protein that contains two RRM domains and was originally identified
as an essenti l trans-acting factor to regulate splicing of the variable exons of Ptprc [65,66]. PSF, like
hnRNPLL, displays preferential binding to the ESS1 element of exon 4 f the Ptprc gene, but its
association with t e ESS1 motif is independent of both hnRNPL and hnRNPLL. PSF does not bind to
the cano ical ARS motif but to sequences out ide of the core m tif [61,66] (Figure 2). R cruitment of PSF
to the CD45 ARS motif requires posttranslational modification of the protei via t serin /threonin
kinas glyc gen sy thase kinase 3 (GSK3). In re ting cells GSK3 phosphorylates PSF which facilitates
its inter tion with TRAP150, and t e PSF-TRAP150 complex prevents PSF form binding to the ARS
motif. Following T cell activation, the a tivity of GSK3 is inhibited which prevents phosphorylation of
PSF and this allows recruitment of PSF to the ARS motif to mediate repression of the variable exons.
Martinez and Ly ch h ve proposed that the PSF-TRAP150 compl x is likely to control a broader set of
alternatively spliced pre-mRNAs in T cells [25].
Int. J. Mol. Sci. 2016, 17, 3 7 of 21
3.4. Serine/Arginine-Rich Splicing Factor 1 (SRSF1)
The SRSF1 protein is a member of the SR protein family and it contains an N-terminal
RRM-domain and a C-terminal RS rich domain which is thought to be involved in protein-protein
interactions. The SRSF1 protein has been implicated in splicing of a number of immune pre-mRNAs
including CD45 exon 5 and for the retention of an intron within the 31 UTR region of the CD3ζ protein
which is involved in the formation of the CD3 complex that is required for TCR signaling. SRSF1
can bind to the ESE sequence in exon 5 of the Ptprc gene. Exon 5 contains two ARS motifs which are
separated by the ESE. SRSF1 can bind to the ESE and promote inclusion of exon 5 whereas hnRNPL can
bind to the ARS sequence and mediate exon repression (Figure 2). It is believed that there is a balance
in the levels of both SRSF1 and hnRNPL at the exon 5 region and depending on which protein is more
abundant this will lead to inclusion or repression of exon 5.
In the context of CD3ζ the level of SRSF1 will determine whether there is intron inclusion or
repression of a specific intron within the 31 UTR of the CD3ζ (Cd247) gene [67]. The inclusion of the
31 UTR intron leads to increased expression of the CD3ζ protein allowing for proper TCR signaling.
When the intron within the 31 UTR is repressed it leads to decreased CD3ζ protein expression and
this can impact on TCR signaling and activation [67]. This could potentially have dangerous effects
on immune tolerance as diminished TCR signaling could lead to escape of self-reactive lymphocytes
during development. It has been noted that low levels of CD3ζ protein correlates with low levels
of SRSF1 and development of the systemic autoimmune disease Systemic Lupus Erythematosus
(SLE) [67].
3.5. The Src-Associated Protein in Mitosis of 68 kDa (Sam68)
Sam68 belongs to the signal transduction and activation of RNA metabolism (STAR) family
of RNA binding proteins that plays a crucial role in regulating cell proliferation, survival and
differentiation across species [68]. The STAR proteins have a KH (hnRNPK homology) domain
embedded within a conserved region referred to as GSG (GRP33/Sam68/GLD1) which is required for
protein–protein interaction and RNA binding. Sam68 has been shown to regulate alternative splicing of
a couple of key target genes in T cells including Cd44 and the generation of the anti-apoptotic isoform
of the apoptotic regulator Bcl-X [69,70]. CD44 is widely expressed on lymphocytes where it functions
in cell homing to lymphoid tissues but also plays a role through embryonic development and tumor
progression [71–74]. There are ten variable exons within the Cd44 gene of which exon 5 is the most
intensively studied variable exon whose splicing is linked to TCR signaling pathways [73,75]. Ras-ERK
signaling promotes interaction of Sam68 with the SR factor SRm160 to form a complex that is recruited
to the ESE of exon 5 to promote exon inclusion [70]. This represents a prime example of how cell
membrane signaling events in response to environmental cues, can modify protein expression within
target cells through alternative splicing to facilitate changes in cell migration. The phosphorylation
of Sam68 by ERK does not affect its affinity for RNA, but rather may be important in directing
protein-protein interactions that facilitate SS recognition and/or spliceosome assembly [70].
In addition to its role in exon inclusion for CD44 exon 5, Sam68 can also bind to the SWI/SNF
complex Brahma (Brm) protein to regulate the rate of RNA Polymerase II (RNAPII) elongation of
mRNA transcripts. Batsche et al. [76] identified that Sam68 and the Brm protein can associate on CD44
exon 5 in response to phorbol 12-myristate 13-acetate stimulation in HeLa cells. The association of
Sam68 with Brm is thought to induce pausing of RNAPII in the variant region of Cd44 exons 4–6. This
mechanism could facilitate inclusion of alternative exons within weak SS’s as the slowing of RNAPII
elongation rates can influence alternative splicing across species [77,78].
Sam68 has been shown to be involved in alternative splicing of the Bcl2l1 gene which encodes
the Bcl-X protein [79]. The Bcl2l1 gene has two 51 SS that are located at a proximal and distal region
within exon 2 of the gene. Depending on which variable SS is used it can yield alternatively spliced
transcripts of the Bcl-X protein that have distinct effects on cell survival [11]. The long form of Bcl-X
(Bcl-XL) has an anti-apoptotic role in lymphocytes and is induced in response to TCR and growth factor
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signaling pathways by splicing from the proximal 51 SS of the Bcl2l1 gene. Alternatively if cells select
the distal 51 SS this leads to generation of the small isoform Bcl-Xs and which has potent apoptotic
activity resulting in cell death [69,80]. Sam68 activity favors the selection of the distal region of exon 2
leading to formation of the Bcl-Xs isoform that induces apoptosis [81]. More recently Bielli et al. [82],
identified a novel transcript factor FBI-1 through a yeast two hybrid screen for proteins that interact
with Sam68. FBI-1 can interact directly with Sam68 and affects its interaction with Bcl2l1 pre-mRNA to
promote splicing of the anti-apoptotic Bcl-XL isoform to protect cell from apoptosis.
3.6. CCCTC Binding Factor (CTCF)
CTCF is a Zinc finger DNA binding protein that was found to bind to exon 5 of Ptprc in cells
that abundantly express the phosphatase enzyme. As mentioned above one of mechanisms that can
promote inclusion of weak upstream exons is the stalling of RNAPII to favor exon inclusion [77,83].
CTCF binding to exon 5 promoted RNAPII pausing upstream of CTCF binding sites and its binding
to the exon 5 site can be inhibited by DNA methylation [84]. This was one of the first documented
studies to show how a protein, normally associated with DNA methylation, could be recruited into the
process of alternative splicing.
3.7. T cell Restricted Intracellular Antigen 1 (TIA-1)
TIA-1 is an RNA binding protein that contains three RRM domains and a glutamine-rich
C-terminal domain. TIA-1 and the related protein TIAR have been implicated in cellular and virus
induced apoptosis [85,86], and also play a role in RNA processing to help silence tumor necrosis factor
(TNF)-α expression [87]. Both proteins also appear to be involved in regulating the skipping of exon 6
on the Fas gene [88]. The Fas exon 6 encodes the transmembrane domain of the protein and thereby
skipping of this exon gives rise to a soluble version of the FAS receptor which plays an important
physiological role to inhibit FAS signaling [89,90]. TIA-1 binds to a uridine rich sequence in the exon 6
51 SS to promote exon 6 inclusion [88]. TIA-1 activity is regulated by posttranslational modification
by the FAS activated serine threonine kinase (FASTK) which is activated in response to FAS ligation
in T cells. Increased FASTK activity promotes TIA1 to induce exon 6 inclusion of FAS leading to
increased production of the full length transmembrane protein FAS that would facilitate cell death.
Izquierdo et al. [91], demonstrated that FASTK activity on Fas alternative splicing required functional
TIA-1 and TIAR proteins as splicing was diminished in the absence of both proteins and was disrupted
by a mutation in the Fas exon 6 51 SS ISE.
4. Immunity versus Tolerance
The immune system has evolved to recognize and destroy foreign microbes and the hallmark
of the adaptive immune system is its ability to recognize and respond to specific antigens and to
generate long lived memory responses [92]. T and B cells are the major effector cells of the adaptive
immune response and the immune system has a diverse repertoire of both cell types to enable the
host to fight infections caused by pathogenic microorganisms. As mentioned T and B lymphocytes
express a clonally restricted antigen specific receptor and during lymphocyte differentiation these
receptors are tested for their reactivity to self-antigens. If the antigen receptor displayed on the surface
of lymphocytes has high affinity for self-antigens the cell will be instructed to undergo apoptosis [92].
This favors the maturation of T and B cells that express antigen receptors with low to moderate affinity
for specific antigen. The selection of antigen specific T and B cells is referred to as central tolerance and
occurs during the process of both T cell development in the thymus and in the bone marrow for B cells.
The development of T and B cells is critical to prevent autoimmunity and autoimmune diseases. In the
following section we would like to highlight a few salient examples where alternations in alternative
splicing can have an important impact on the outcome of fundamental processes within the immune
system that control apoptosis, lymphocyte homeostasis and B cell responses.
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5. Control of Apoptotic Effector Proteins by Alternative Splicing
The strength of TCR or BCR signaling in developing lymphocytes is crucial in determining the
outcome of central tolerance as is the ability to eliminate autoreactive lymphocytes by apoptosis [93,94].
Much has been learnt about the proximal and distal biochemical signaling pathways that emanate from
the TCR and BCR. These studies have identified a number of cell surface proteins that facilitate the
initial stages of antigen receptor signaling and are crucial for transducing signals from the membrane
into the cytoplasm and nucleus to regulate gene expression [95]. A number of key factors have been
identified that control the choice between immunity and tolerance at the level of cell survival. Some of
these factors require pre-mRNA alternative splicing that give rise to specific protein isoforms. If the
splicing of a key target gene is disrupted in any way it can have an important impact on the final
outcome of health and disease.
A number of apoptotic regulators have been shown to undergo alternative splicing [32]. Proteins
that belong to the TNF superfamily function as death receptors or death ligands to induce apoptotic
signaling pathways to mediate cell death [11,96]. These proteins play important roles in variety of
setting including embryonic development, in the immune system to regulate immune homeostasis
and the resolution of immune responses following pathogen clearance. One of the death receptors
widely expressed by lymphocytes include the FAS receptor (CD95) which interacts with the FAS ligand
(FASL, CD95L). A soluble form of FAS can be generated by alternative splicing via exon skipping
of the variable exon 6 of the Fas gene that lacks the transmembrane domain to yield a soluble FAS
protein which can inhibit apoptosis via the FAS receptor pathway [97,98]. As mentioned above the
TIA-1 and TIAR hnRNP proteins are key trans-acting factors that regulate exon 6 inclusion to mediate
expression of the full length FAS protein [88]. The activity of TIA-1 is controlled through a feed-forward
regulatory pathway where by activation of FAS signaling in the T cell leads to increased activity of
FASTK which phosphorylates TIA-1. This facilitates the recruitment to the exon 6 ISE to mediate exon
inclusion [91]. A number of studies have identified different spliced isoforms of the FAS in activated
human peripheral blood mononuclear cells and in T cell tumor lines [97,98]. Further highlighting the
important role for the regulation of pre-mRNA splicing of death receptor proteins is the observation
that elevated levels of soluble FAS are detected in the serum of patients with the autoimmune disease
SLE and other malignancies [90].
The induction of apoptosis is dependent on a well-conserved signaling pathway that leads to
inhibition of pro-survival proteins such as Bcl-2 and Bcl-XL, but upregulation of a range of pro-apoptotic
proteins such as the Bcl-2-like 11 protein (also known as Bcl-2-interacting mediator of cell death, Bim),
Bcl-2 associated X protein (Bax) and Bak that lead to apoptosis and cell death [11]. As discussed above
the Bcl-XL protein functions to promote cell survival like Bcl-2, but the Bcl2l1 gene can be alternatively
spliced to yield different isoforms with distinct biological activities. The Sam68 protein promotes
the use of the distal 51 SS to yield the Bcl-Xs isoform [69]. In addition, exposure of cells to ceramide,
a known proapoptotic inducer, can preferentially promote splicing of the Bcl-Xs isoform to promote cell
death [69,99–101]. In contrast, the FBI protein can interact with Sam68 to promote splicing of the Bcl2l1
gene from the proximal 51 SS to give rise to the long isoform Bcl-XL that protect cells from apoptosis.
The Bcl2l11 gene, encoding another pro-apoptotic member Bim, undergoes pre-mRNA alternative
splicing to yield three different isoforms (BimS, BimL, BimEL) that differ in their capacity to induce
apoptosis [102–104]. Bim plays a critical role in inducing cell death in the thymus and is required
to eliminate self-reactive T cells [102]. The most effective inducer of apoptosis is the BimS isoform,
while BimL and BimEL have the least apoptotic activity [104,105]. Analysis of Bim´{´ mice revealed
that these animals contained 2–3 times more T and B cells compared to wild type littermates and
displayed lymphadenopathy with increasing age. Bim´{´ mice also developed higher levels of
autoreactive antibodies with an increase in autoreactive IgG antibodies to nuclear antigens and
deposits of immune complexes in the kidneys consistent with a Lupus like autoimmune disease [105].
These data highlight that the levels of Bim are important for maintaining lymphocyte homeostasis and
to protect against autoimmunity.
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Both cis-elements and trans-acting factors contribute to pre-mRNA alternative splicing of
Bcl2l11 that promotes inclusion of either Bcl2l11 exons 3 or 4 and this can give rise to two distinct
mRNA isoforms. Exons 3 and 4 cannot be spliced together because exon 3 contains a functional
polyadenylation signal and lacks a functional 51 SS. Exon 3 containing splice variants are not
proapoptotic because they lack the BH3 domain encoded in exon 4 which is involved in interacting and
antagonizing the pro-survival members of Bcl-2 family [104,106]. Overexpression of the splicing factor
SRSF1 promotes inclusion of exon 3 over exon 4 and this favors the expression of non-apoptotic splice
variants of Bim in mammary epithelial cells [106]. In addition, a single nucleotide polymorphism
(SNP) in exon 4 of Bcl2l11 can cause exon skipping of exon 3 that is dependent on trans-acting factors
PTBP1 and hnRNPC [107] and the splicing factor SRSF6 [108].
6. Alternative Splicing and Control of T Cell Activation
Control of T cell activation is crucial to prevent inappropriate activation of mature effector
T cells. The CD28 receptor expressed on TCRαβ+ cells is involved in costimulation of T cell responses
to drive full activation of the cell. The CTLA-4 protein is upregulated on activated T cells and
has been shown to play a critical role in dampening TCR signaling in activated T cells and inhibit
cellular proliferation and function [109–112]. The CTLA-4 receptor has 4–5-fold higher affinity for the
CD80/CD86 ligands expressed by professional antigen presenting cells than that of the costimulatory
receptor CD28 [111,112].
Recent studies by Butte et al. [113], identified that T cell activation via TCR and CD28 signaling
leads to increased splicing of a wide range of target genes. They found a range of target genes, some of
which were known to be controlled by hnRNPLL [63] that underwent alternative splicing in response to
TCR/CD28 signaling compared to TCR signaling alone [113]. This was the first report to demonstrate
that costimulatory signals in T cells induce a program of alternative splicing. The costimulatory signal
emanating from CD28 is crucial to prevent T cell clonal anergy in naive T cells following recognition of
their antigen. Expression of the Hnrnpll gene was increased upon CD28 costimulation [113].
Ctla4´{´ mice rapidly develop lymphoproliferative diseases with multi-organ infiltration and
tissue destruction [114–116]. It is not surprising that the Ctla4 gene has been identified as an
autoimmunity susceptibility gene in a number of autoimmune diseases including type 1 diabetes,
multiple sclerosis and Graves’ disease [117–119]. Mapping studies in humans identified a variation in
the noncoding 31 region of CTLA4 which correlated with lower mRNA levels of the soluble form of
CTLA-4 protein [119]. The novel splice variant termed liCTLA-4 lacked the exon 2 which encoded the
CD80/CD86 ligand binding domain. It is believed that liCTLA-4 would act by inhibiting T cell
activation and expansion and is therefore important for maintenance of immune tolerance and
homeostasis and an equivalent spliced isoform was verified in mice [119,120]. However the specific
cis-elements and trans-acting factors responsible for generating the spliced variant of CTLA-4 have yet
to be described.
7. Control of T Cell Homeostasis
The immune system maintains tight control over lymphocyte numbers in the peripheral
circulation that is determined by growth factor signaling through the common gamma chain (γc) family
of receptors predominantly IL-7, IL-15 and IL-2 [121]. Disruption to growth factor signaling through
growth factor withdrawal can promote cell death by apoptosis. A failure to maintain stable numbers
of lymphocytes in the immune system, especially CD4+ Foxp3+ regulatory T cells above a critical
level can lead to a breakdown in self-tolerance and development of spontaneous autoimmunity [121].
The IL-7 receptor (IL-7R) is composed of IL-7Rα which helps to form the high affinity receptor, that
pairs with the IL-2Rβ subunits and the γc chain. Signaling via the IL-7R is critical to maintain stable
numbers of CD4+ and CD8+ T cells in the peripheral circulation of the immune system. The Il7r gene
can undergo alternative splicing. For example the variable exon 6 that encodes the transmembrane
domain of the receptor can be skipped to give rise to a soluble version of the receptor. A SNP within
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the exon 6 of IL7R has been identified in patients with multiple sclerosis that leads to skipping of exon
6 leading to increased levels of soluble IL-7Rα [122–124]. Splicing of the cytokine Il7 gene has also
been observed and various spliced forms of the IL-7 have been identified in granulomatous lesions of
Mycobacteria tuberculosis patients and in transformed tissues and tumor cell lines [125]. Moreover, the
study by Vudattu et al. [125], identified that skipping of exon 5 in the Il7 gene led to increased STAT5
signaling via the IL-7R to promote T cell survival. More recent studies have identified an important
role for pre-mRNA alternative splicing as a factor that contributes to the long-term survival of naïve
CD4+ and CD8+ T cells in the peripheral immune system [26].
A novel allele of hnRNPLL was isolated through an ENU mutagenesis screen in mice to identify
genes that regulate lymphocyte differentiation and homeostasis [126]. The novel allele was identified
through genetic mapping in mice that displayed a significant decrease in CD4+ and CD8+ T cell
numbers in the peripheral circulation [26]. The mutation was mapped to the Hnrnpll gene and was
designated “thunder” for “Th cells under the normal range” [26]. The mutation leads to a single amino
acid substitution of a conserved valine residue for aspartate V136D within the RRM1 domain in the
Hnrnpll gene. The valine residue is highly conserved in vertebrates and other similar domains in
hnRNP proteins [26]. The V136D mutation did not affect binding affinity but rather greatly decreased
the protein’s stability of the RRM1 domain leading to a loss of function [26]. Thunder mice have
a 20 to 200 fold increase in CD45RA, RB and RC isoforms without increasing the overall surface
expression of CD45 [26,127,128]. Furthermore, these mice cannot splice the Ptprc gene which gives
rise to constitutive expression of the high molecular weight CD45RABC isoform in thymocytes and
peripheral T cells within peripheral lymphoid tissue [26]. Initially at birth and in the first couple of
weeks during postnatal development there is no significant difference in T cell numbers between wild
type mice, but as the Thunder mice aged the CD44l0 (naïve) cell subset failed to accumulate normally
in peripheral blood, spleen and lymph nodes. Furthermore there was a marked decline in naïve T cells
by 4–6 weeks of age due to a T-cell intrinsic decrease in their persistence [26]. The demise of peripheral
naïve T cells was compensated by an increase in CD44hi memory phenotype T cells [26]. Interestingly,
the lymphopenia observed in the hnRNPLLthunder mice did not increase their chances of developing
spontaneous autoimmune disease and when hnRNPLLthunder mutation was bred onto a TCRHEL ˆ
InsHEL double transgenic background the mice were not predisposed to developing autoimmune
diabetes [26,127].
Initially it was thought that the lymphopenia in hnRNPLLthunder mice was due to aberrant T cell
signaling due to the lack of low molecular weight CD45 isoforms [26,127]. However, it was later shown
that the hnRNPLLthunder mutation disrupted peripheral T cell accumulation even in the absence of
the CD45 protein [127]. It was concluded that hnRNPLL has a further role to play in regulating cell
viability that is independent of its role in regulating CD45 alternative splicing. [127]. It would appear
that the abundance of CD45 at the cell surface is more important for T cell differentiation in the thymus
than the expression of different CD45 isoforms [127,129].
We further described that hnRNPLL seems to be more important to control the numbers of
CD4+ and CD8+ T cells than other T cell populations. It was discovered that NKT cells accumulated
normally in the thymus and periphery of hnRNPLLthunder mice, despite the overlapping requirement
for hnRNPLL in regulation of alternative splicing of the Ptprc pre-mRNA in NKT cells and TCRαβ+
cells [128]. Interestingly, the expression of developmentally regulated cell surface marker NK1.1 on
NKT cells was significantly reduced in hnRNPLLthunder mice [128], revealing again divergent roles for
hnRNPLL in different lymphocyte subsets.
8. Alternative Splicing in B Cells and the Role of hnRNPLL in B Cell Development and Function
B cells with their ability to secrete a large amount of antibodies against various evolving pathogens
are important players of the adaptive immune system. B cells develop in the bone marrow of most
mammals in a highly regulated process that depends on cell intrinsic and extrinsic factors as well as
the activation of transcription factors [130,131]. In order for B cells to generate a diverse repertoire
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of antigen receptors, Ig heavy and light chain rearrangements occur in precursor B cells in the bone
marrow. Successful production of heavy and light chains allows precursor B cells to express IgM
on the cell-surface. These cells, called immature B cells, are ready to leave the bone marrow and
enter the periphery to complete their maturation. However, immature B cells need to be checked first
for self-reactivity before they leave the bone marrow, if they express receptors with high affinity for
self-antigens they must be either eliminated or silenced in order to maintain self-tolerance through
several mechanisms which include receptor editing [132–135], clonal deletion [136] and anergy [137].
Immature B cells that pass the initial check-point begin expressing IgD on their surface and migrate to
the spleen for their final stages of maturation into different subsets including follicular and marginal
zone B cells [138]. The mature BCRs on B cells are in the form of membrane-bound Ig molecules
and search for their cognate antigens during their circulation in the blood and lymph. When a BCR
recognizes epitopes on a protein antigen the B cell becomes activated and differentiates into either an
antibody producing plasma cell that secretes a soluble form of antigen specific Ig molecules to clear
the pathogen, or differentiate into memory B cells to provide a faster and stronger immune response
upon a secondary encounter with the same antigen.
There are five different antibody isotypes made by B cells namely IgM, IgD, IgG, IgE and IgA,
which differ in their heavy chain isotypes produced from a single Ig heavy chain (Igh). These isotypes
are produced at distinct stages of B cell lymphopoiesis and function as maturation markers, receptors
(membrane-bound form), and effector molecules during the clearance of antigens (secreted-form).
While IgG, IgE and IgA are produced by irreversible rearrangement of the gene after activation
(called class switching), IgM and IgD are co-expressed through alternative splicing of a long primary
mRNA transcript from the Igh locus [139,140], which is conserved in many species [141]. However, it
remains unclear how alternative splicing of the VDJH sequences to those exons encoding the constant
regions of IgM and IgD is developmentally regulated during B cell maturation. The trans-acting factor
hnRNPLL could be a candidate for controlling pre-mRNA processing during B cell development, but
splenic B cells from hnRNPLLthunder mice have normal IgM and IgD expression (unpublished data).
This suggests that hnRNPLL is most likely dispensable for alternative splicing of Igh. Interestingly
two independent groups recently identified zing-finger protein (ZFP) 318 to act as a regulator of
IgD expression on mature B cells [142,143]. Mice deficient in ZFP318 exhibit a largely normal B cell
phenotype, but all mature B cells fail to express IgD and display heightened IgM expression on the
surface [142,143]. Consistent with its function in IgD production, mRNA levels of Zfp318 in IgD+ B
cells is higher compared to other IgD´ subsets [142–144]. These findings suggest the Ighd splicing is
promoted during the maturation of B cells into IgD-expressing cells and this process is controlled by
ZFP318 [142,143].
Upon activation B cells can differentiate into antibody-producing plasma cells and pre-mRNA
splicing occurs to increase the synthesis of Ighg2b mRNA transcript encoding the secreted Ig [145],
through alternative splicing of Igh genes at their 31 ends [146–148]. However, the mechanism for
posttranscriptional regulation of this process remains obscure. In order to identify pre-mRNA splicing
regulator(s) of Igh in B cells, the Rao group compared the transcriptional profiles of bone marrow
plasma cells versus naïve B cells. Both Hnrnpll mRNA and protein expression was significantly
increased in plasma cells compared with naïve B cells [149]. Consistent with increased expression in
plasma cells, the authors were able to identify the hnRNPLL binding sites within Ighg2b transcripts
using PAR-CLIP. Given that the secreted Ighg2b mRNA is higher in plasma cells compared to naïve B
cells with increased membrane-encoding Ighg2b [145], one can suggest that hnRNPLL might play a role
in RNA processing to help generate the secretory-specific form of Igh mRNA versus membrane-bound
form. However, the ratio of membrane Ighg2b to secreted Ighg2b was surprisingly reduced in a mouse
plasmacytoma cell line that lacked hnRNPLL [149]. Thus, it is possible that the role of hnRNPLL in
driving production of secreted Ighg2b in plasma cells somehow is masked and/or counteracted by
other trans-acting factor(s). In keeping with this notion, the transcription elongation factor ELL2 has
been shown to control accumulation of the secretory form of Ighg2b mRNA by plasma cells [149–151].
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A report by Chang et al. [152], revealed that the role of hnRNPLL in B cell development
and function goes beyond its impact on the regulation of Ighg2b transcripts. They used retroviral
transduction of bone marrow cells that contained either shRNA knockdown of hnRNPLL or a control
vector. The transduced bone marrow cells were transferred to irradiated recipients. B cell development
in both groups of recipient mice was normal but the total number of mature B cells observed in the
peripheral circulation of irradiated mice reconstituted with sh-hnRNPLL knock down bone marrow
cells, was significantly reduced compared to control animals that received bone marrow containing
the control sh-scramble [152]. These data suggest a possible role of hnRNPLL in the development of B
cells in the bone marrow and/or periphery, which requires further examination. Moreover, hnRNPLL
has also been shown to be involved in the differentiation of plasma cells in vitro and in vivo [152].
Since the differentiation of plasma cells from B cells is associated with exclusion of CD45 exons
4–6 [153,154], it is possible that hnRNPLL may control the switch to the CD45RO isoform during
plasma cell differentiation. Indeed, in addition to its role in regulation of alternative splicing of exon
4, 5 and 6 in T cells, Chang et al. [152], showed that hnRNPLL selectively controls skipping of exon 4
during plasma cell differentiation. However, it remains unclear whether or not the inability to exclude
exon 4 underlies the defect in plasma cell differentiation. Despite the evidence that hnRNPLL might
mediate plasma cell differentiation it remains unclear if it can affect splicing of other master regulatory
genes such as Irf4 that are required for plasma cell differentiation [152,155,156], or whether hnRNPLL
may have a more global effect on alternative splicing events to facilitate plasma cell differentiation.
Chang et al. [152], used the PAR-CLIP assay to reveal the hnRNPLL-binding sites on plasmacytoma
RNAs that are related to the regulation of alternative processing of pre-mRNAs. HnRNPLL has been
shown preferentially to bind to CA dinucleotide-containing RNA sequences in introns. Furthermore,
10% of the hnRNPLL-recognition sites were found to be within the 31 UTR regions, which upon binding
possibly promote mRNA stability [152]. Thus, these findings reinforce the critical role for hnRNPLL in
alternative splicing of pre-mRNAs, and extend our understanding of the posttranscriptional regulation
of mRNAs during the differentiation of immune cells upon activation.
9. Future Directions
The development of new molecular techniques have enabled scientists to learn more about the
broader networks that regulate gene expression and alternative splicing within cells. The use of array
technologies such as gene expression microarrays and exon arrays have uncovered the breadth of
global changes to gene expression and splicing events that occur in response to cellular activation
and differentiation. As previously highlighted by Martinez and Lynch [31] in order to gain a deeper
understanding of splicing programs within specific cells there is a need to validate the splicing of
predicted genes that are derived from the different assays by PCR or protein expression, which is
something that has not been performed in all studies.
The use of cell based assay systems have demonstrated a strength to uncover key trans-acting
factors that control alternative splicing in lymphocytes. However, the limitation of these studies is that
it is difficult to examine how they would affect specific cellular responses to infection or immunization
in vivo. The isolation of the hnRNPLLthunder allele in a novel mouse strain provides a good example of
how mutagenesis approaches can facilitate knowledge about the biological functions of regulatory
proteins. Identification of the hnRNPLLthunder allele helped to understand the physiological effects
of altering a single splicing regulator and its impact on the immune system. The hnRNPLL protein
plays a global role in regulating alternative splicing of CD45 in lymphoid and non-lymphoid cells,
but its effects on cellular homeostasis appears restricted to naïve TCRαβ+ cells. This highlights the
need for a broader understanding of the global signaling pathways that emanate from the surface via
antigen and/or growth factor receptors and how these are coordinated to regulate the program of
alternative splicing within a single cell. The biochemical signaling pathways that function downstream
from the TCR, BCR, growth factor receptors and death receptors like FAS have been well described.
Yet we still know little about how these key signals link the control of cell growth and survival to the
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activity of splicing factors. The use of conditional gene targeting and development of the CRISPR/Cas9
techniques for gene editing either in vitro or in vivo should also allow scientists to target specific hnRNP
proteins within specific cell types to study their function. This could help to elucidate the roles of
individual hnRNP proteins in vivo and uncover the broader global networks of interaction between
proteins and genes that control alternative splicing. The recent studies highlighting the role of DNA
binding nuclear factors and their effect on RNAPII stalling on exons highlights just how much more we
have to learn about the molecular interactions that help control gene expression, alternative splicing
and translation.
10. Conclusions
In conclusion, we have highlighted the important role for pre-mRNA alternative splicing in a
number of key immune functions that can have an impact on the decision between immunity and
tolerance. SR splicing factors and hnRNP proteins act as trans-acting factors to mediate exon inclusion
or exon skipping of genes and their activity is tightly linked to cellular and environmental cues that
impact on cell differentiation and maturation. The immune system relies on apoptosis to remove
autoreactive cells and effector T cells at the resolution of infection. We have discussed how alternative
splicing is used to control the activity of apoptotic effector proteins such as FAS, Bcl-X and Bim and how
strength of antigen receptor signaling and other cell surface molecules such as CD45 and CTLA-4 can
affect T and B cell responses. Clearly more needs to be learnt about the regulation in alternative splicing
but as our understanding grows it may help scientists to develop therapeutic interventions where
dysregulation in alternative splicing defects contribute to human disease that will not be restricted to
just the immune system [157].
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